PRESS RELEASE | Euformatics partners with Appolon Bioteck to expand in the French market
Espoo, September 6th, 2023. Euformatics, a Finnish bioinformatics company that develops world-leading genomic data analysis tools, announced that it
PRESS RELEASE | Euformatics expands in the Middle East in partnership with Zahrawi Medical Group for Bahrain, Oman and the UAE markets
Espoo, Finland, May 2023. Euformatics, a Finnish bioinformatics company that develops world-leading NGS interpretation and quality control tools,
PRESS RELEASE | Euformatics and ViennaLab join forces to develop a complete and efficient solution for species level classification of the human gut microbiome.
Espoo, Finland, March 2023. Research points out that microorganisms play a role in many aspects of human health. Consequently, more and more people
PRESS RELEASE | Euformatics, in partnership with ViennaLab Diagnostics and Oncompass Medicine, awarded a contract to research and develop an end-to-end liquid biopsy solution for eight leading European oncology centers
Espoo, Finland, February 2023. Euformatics, a global leader in NGS data quality control and variant interpretation, together with ViennaLab
PRESS RELEASE | Folkhälsan Research Center chooses Euformatics Genomics Hub end to end solution for clinical research of NGS patient data
Espoo, Finland, January 2023. Folkhälsan Research Center, has chosen Euformatics as the provider of NGS secondary analysis and variant
PRESS RELEASE | Euformatics awarded a contract to deliver cancer diagnostics to seven European hospitals in collaboration with BC Platforms and Oncompass Medicine
Espoo, Finland, December 2022. Euformatics, a global leader in NGS data quality control and variant interpretation, together with Finland’s BC
PRESS RELEASE | Euformatics offering variant interpretation services to the Colombian Alife Health through Quimiolab.
HELSINKI, Finland, September 2022. Euformatics, a Finnish company providing services for NGS variant interpretation and quality control, had
